focus -WSS

focus

author：comprehensive 2025-08-26 02:45:34 - browse：722

Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from wastes of time when it comes to AI in biotech.

For more on what we cover, here’s the latest on AI in drug development; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Study on Amgen’s bispecific immunotherapy produces positive data

WSS

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Why depression after traumatic brain injury is distinct

HHS secretary Becerra pressed on Change HealthCare cyberattack

STAT Summit: Ending the crisis of Black deaths in the U.S.

Is there really a nursing shortage in the U.S.?

Roivant's CEO is a star, but biotech's black hole persists

hotspot

focus

focus

Activists slam private health insurers over coverage restrictions

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Bright Health sells Medicare Advantage business to Molina

RaDonda Vaught links Vanderbilt hospital issues to patient death

How to save PrEP access — and even expand it

Smaller biotechs seek to piggyback on weight loss drug boom

Psychedelics group wrestles with new pharma identity

Boston's new lab space is opening empty

leisure time

STAT Summit: Meghan O’Rourke on making chronic illness visible

Roche acquires Telavant from Roivant, adding experimental IBD treatment

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Steward Health Care Massachusetts hospitals face fiscal disaster

Boston's new lab space is opening empty

Health tech investors get more selective as pandemic boom fades

Wikipedia

entertainment

entertainment

hotspot